Hadassah

FDA Approves US Clinical Trials to Treat ALS with Israel Stem Cell Technology

Wednesday, Apr 30 2014

The United States Food and Drug Administration (FDA) has approved the start of multi-center Phase II clinical trials in the United States to treat amyotrophic lateral sclerosis (ALS) with adult stem cell technology first introduced by the Hadassah Medical Organization’s Prof. Dimitrios Karussis, Senior Neurologist and head of Hadassah’s Multiple Sclerosis Center.

The treatment, developed by Israel’s BrainStorm Cell Therapeutics, involves injecting autologous stem cells (coming from the patients themselves) into the spinal fluid. Earlier clinical trials at Hadassah have shown that the treatment was both well tolerated and safe. “Ten of the 15 patients in the Hadassah trials responded or stabilized,” reports Prof. Karussis, “and the disease was halted, with their breathing improved. About three of them even showed that the disease had receded, with them improving dramatically.” He notes, however, that the treatment is not a permanent cure. The injection “probably has to be repeated after several months.”

Trials will begin at Massachusetts General Hospital in Boston and the University of Massachusetts Memorial Hospital in Worcester and later be initiated at the Mayo Clinic in Minnesota.
Read more in The Jerusalem Post

Related Stories

alt_text

Thursday, Oct 17 2019

Where are we with Alzheimer’s? Hadassah Doctor Provides His Perspective

With the chance that any one of us could acquire Alzheimer’s disease doubling every five years after age 60, Prof. Tamir Ben-Hur...

READ MORE ›
alt_text

Thursday, Oct 17 2019

Three More Years: An Unprecedented Extension of Life

Gerald Lieder, age 94, passed away this month. Three years ago, his family gathered from the United States and Israel to say goodbye to him because his heart was failing.

READ MORE ›
alt_text

Thursday, Oct 17 2019

Hadassah Study Sheds Encouraging Light in Treating Liver Disease

The International Journal of Molecular Medicine has published a pre-clinical study led by Prof. Rifaat Safadi, head of the Hadassah Medical Organization’s Liver Unit...

READ MORE ›
alt_text

Thursday, Oct 17 2019

Vaginal Microbiome Transplant Proves Effective Against Bacterial Vaginosis

A new treatment developed by Hadassah Medical Organization and Weizmann Institute of Science researchers, involving a vaginal microbiome transplant...

READ MORE ›
SUPPORT HADASSAH HOSPITALS

Learn more about the Hadassah Medical Organization.

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More